Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MGTX |
---|---|---|
09:32 ET | 609 | 4.24 |
09:39 ET | 100 | 4.24 |
09:41 ET | 100 | 4.24 |
09:43 ET | 200 | 4.22 |
09:48 ET | 300 | 4.22 |
09:50 ET | 4921 | 4.16 |
09:52 ET | 2000 | 4.175 |
09:57 ET | 2000 | 4.1897 |
10:01 ET | 100 | 4.175 |
10:08 ET | 4301 | 4.18 |
10:10 ET | 200 | 4.2 |
10:12 ET | 900 | 4.18 |
10:14 ET | 1213 | 4.2 |
10:15 ET | 7163 | 4.205 |
10:17 ET | 1400 | 4.25 |
10:21 ET | 200 | 4.255 |
10:24 ET | 300 | 4.255 |
10:26 ET | 394 | 4.255 |
10:32 ET | 174 | 4.26 |
10:35 ET | 200 | 4.26 |
10:37 ET | 300 | 4.26 |
10:42 ET | 511 | 4.24 |
10:44 ET | 417 | 4.23 |
10:55 ET | 200 | 4.24 |
10:57 ET | 100 | 4.24 |
11:00 ET | 100 | 4.24 |
11:02 ET | 956 | 4.22 |
11:13 ET | 400 | 4.22 |
11:20 ET | 200 | 4.23 |
11:22 ET | 100 | 4.23 |
11:26 ET | 200 | 4.24 |
11:27 ET | 100 | 4.235 |
11:29 ET | 1417 | 4.245 |
11:31 ET | 200 | 4.245 |
11:36 ET | 100 | 4.245 |
11:38 ET | 115 | 4.26 |
11:42 ET | 600 | 4.25 |
11:44 ET | 300 | 4.26 |
11:45 ET | 100 | 4.26 |
11:47 ET | 760 | 4.25 |
11:49 ET | 269 | 4.23 |
11:51 ET | 1200 | 4.25 |
11:54 ET | 100 | 4.25 |
11:56 ET | 446 | 4.25 |
12:00 ET | 300 | 4.27 |
12:02 ET | 448 | 4.25 |
12:03 ET | 100 | 4.265 |
12:07 ET | 304 | 4.28 |
12:12 ET | 100 | 4.28 |
12:14 ET | 200 | 4.28 |
12:16 ET | 129 | 4.27 |
12:18 ET | 200 | 4.28 |
12:20 ET | 300 | 4.28 |
12:21 ET | 100 | 4.28 |
12:25 ET | 600 | 4.27 |
12:27 ET | 1130 | 4.27 |
12:30 ET | 226 | 4.27 |
12:32 ET | 200 | 4.27 |
12:34 ET | 300 | 4.27 |
12:38 ET | 300 | 4.27 |
12:39 ET | 200 | 4.27 |
12:41 ET | 520 | 4.28 |
12:48 ET | 596 | 4.27 |
12:50 ET | 100 | 4.28 |
12:52 ET | 300 | 4.27 |
12:54 ET | 400 | 4.27 |
12:56 ET | 100 | 4.27 |
12:57 ET | 200 | 4.27 |
12:59 ET | 200 | 4.27 |
01:03 ET | 301 | 4.27 |
01:06 ET | 200 | 4.27 |
01:10 ET | 200 | 4.27 |
01:12 ET | 105 | 4.28 |
01:14 ET | 800 | 4.27 |
01:15 ET | 300 | 4.27 |
01:17 ET | 300 | 4.27 |
01:19 ET | 200 | 4.27 |
01:21 ET | 100 | 4.27 |
01:26 ET | 711 | 4.28 |
01:28 ET | 100 | 4.29 |
01:30 ET | 700 | 4.29 |
01:32 ET | 100 | 4.29 |
01:35 ET | 200 | 4.3 |
01:37 ET | 200 | 4.3 |
01:42 ET | 200 | 4.3 |
01:44 ET | 200 | 4.3 |
01:48 ET | 200 | 4.3 |
01:50 ET | 200 | 4.3 |
01:51 ET | 437 | 4.3 |
01:53 ET | 540 | 4.3 |
01:55 ET | 200 | 4.31 |
01:57 ET | 800 | 4.3 |
02:00 ET | 193 | 4.3 |
02:02 ET | 1000 | 4.3 |
02:04 ET | 800 | 4.31 |
02:08 ET | 100 | 4.31 |
02:09 ET | 1416 | 4.3 |
02:18 ET | 400 | 4.3 |
02:20 ET | 602 | 4.31 |
02:22 ET | 585 | 4.3 |
02:24 ET | 104 | 4.305 |
02:26 ET | 200 | 4.305 |
02:27 ET | 820 | 4.31 |
02:29 ET | 200 | 4.305 |
02:31 ET | 600 | 4.29 |
02:33 ET | 200 | 4.29 |
02:38 ET | 701 | 4.29 |
02:40 ET | 200 | 4.29 |
02:42 ET | 200 | 4.29 |
02:44 ET | 3052 | 4.25 |
02:47 ET | 400 | 4.25 |
02:51 ET | 977 | 4.24 |
02:56 ET | 100 | 4.23 |
03:00 ET | 100 | 4.24 |
03:03 ET | 817 | 4.23 |
03:05 ET | 900 | 4.24 |
03:07 ET | 204 | 4.24 |
03:12 ET | 445 | 4.23 |
03:14 ET | 300 | 4.23 |
03:16 ET | 100 | 4.23 |
03:18 ET | 2130 | 4.2 |
03:20 ET | 451 | 4.2 |
03:25 ET | 300 | 4.2 |
03:27 ET | 1049 | 4.2 |
03:36 ET | 2150 | 4.2 |
03:38 ET | 400 | 4.21 |
03:39 ET | 200 | 4.21 |
03:41 ET | 220 | 4.21 |
03:43 ET | 400 | 4.22 |
03:45 ET | 639 | 4.21 |
03:48 ET | 400 | 4.22 |
03:50 ET | 796 | 4.22 |
03:52 ET | 2602 | 4.26 |
03:54 ET | 647 | 4.26 |
03:56 ET | 4096 | 4.28 |
03:57 ET | 4450 | 4.24 |
03:59 ET | 55610 | 4.21 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
MeiraGTx Holdings PLC | 270.7M | -3.3x | --- |
Molecular Partners AG | 266.2M | -3.6x | --- |
Uniqure NV | 217.5M | -0.7x | --- |
XOMA Corp | 275.7M | -6.0x | --- |
TScan Therapeutics Inc | 309.2M | -4.6x | --- |
C4 Therapeutics Inc | 317.9M | -1.9x | --- |
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $270.7M |
---|---|
Revenue (TTM) | $11.4M |
Shares Outstanding | 64.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.33 |
EPS | $-1.27 |
Book Value | $2.17 |
P/E Ratio | -3.3x |
Price/Sales (TTM) | 23.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,336.32% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.